WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will participate in the Morgan Stanley Global Healthcare Conference. Consistent with the Conference’s format, ImmunoGen President and CEO Daniel Junius will discuss the Company in a moderated question and answer session that will be webcast beginning at 9:55am ET on September 8, 2014.
Help employers find you! Check out all the jobs and post your resume.
